Werewolf Therapeutics (HOWL) Other Non-Current Liabilities (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Other Non-Current Liabilities of $85000.0 for Q1 2026, down 96.8% year-over-year from $2.7 million in Q1 2025, and down 88.8% on a QoQ basis from $759000.0 in Q4 2025.
Werewolf Therapeutics (HOWL) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Other Non-Current Liabilities for 5 years, with the latest figure at $85000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $85000.0, down 96.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $85000.0 (down 96.8% YoY), and the FY2025 annual result was $759000.0, down 73.17% from the prior year.
- Other Non-Current Liabilities retreated to $85000.0 in Q1 2026, from $759000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $2.8 million in Q2 2024 and troughed at $85000.0 in Q1 2026.
- A 4-year average of $1.6 million and a median of $2.6 million in 2025 frame the typical range for Other Non-Current Liabilities.
- The widest annual swing landed in 2025, when Other Non-Current Liabilities declined 4.42%; it then slumped 96.8% in 2026.
- A 4-year view of Other Non-Current Liabilities shows it stood at $191000.0 in 2022, then surged by 1381.15% to $2.8 million in 2024, then tumbled by 73.17% to $759000.0 in 2025, then tumbled by 88.8% to $85000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $85000.0 in Q1 2026, $759000.0 in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85,000.00 |
| Dec 31, 2025 | 759,000.00 |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | 2.84 Mn |
| Dec 31, 2022 | 191,000.00 |
| Sep 30, 2022 | 191,000.00 |
| Jun 30, 2022 | 191,000.00 |
| Dec 31, 2020 | 31,000.00 |